Novo Nordisk A/S (CPH:NOVO.B)
Denmark · Delayed Price · Currency is DKK 350.00
-10.50 (-2.91%)
Sep 5, 2025, 4:59 PM CET
Novo Nordisk Revenue
Novo Nordisk had revenue of 76.86B DKK in the quarter ending June 30, 2025, with 12.93% growth. This brings the company's revenue in the last twelve months to 311.94B, up 20.90% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
311.94B
Revenue Growth
+20.90%
P/S Ratio
4.99
Revenue / Employee
3.98M
Employees
77,349
Market Cap
1,555.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Coloplast | 27.87B |
| Genmab | 23.16B |
| Demant | 22.59B |
| ALK-Abelló | 5.86B |
| H. Lundbeck | 23.52B |
| Zealand Pharma | 9.11B |
| Ambu A/S | 5.96B |
| Bavarian Nordic | 6.46B |
Novo Nordisk News
- 12 hours ago - Novo Nordisk: Keep It Low So I Can Keep Accumulating (Rating Upgrade) - Seeking Alpha
- 13 hours ago - September 30, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NVO - GlobeNewsWire
- 14 hours ago - Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PRNewsWire
- 16 hours ago - Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data - Benzinga
- 17 hours ago - Novo Nordisk Vs Eli Lilly: Novo A Clear Winner - Seeking Alpha
- 21 hours ago - Novo Nordisk A/S Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO - PRNewsWire
- 1 day ago - Novo Nordisk to present new semaglutide data on ‘food noise', body composition and cardiovascular benefits, as well as pipeline data at the EASD diabetes congress - GlobeNewsWire
- 1 day ago - Novo Nordisk A/S Class Action: The Gross Law Firm Reminds Novo Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 30, 2025 – NVO - GlobeNewsWire